Oliver Sartor

Oliver Sartor

Oliver Sartor is an internationally renowned oncologist specializing in prostate cancer research and practice. He serves as past Chairman of the Department of Defense Prostate Cancer Integration Panel, Editor-in-Chief of Clinical Genitourinary Cancer Journal, as well as C.E. and Bernadine Laborde Professor of Cancer Research for both Medicine and Urology Departments at Tulane University School of Medicine New Orleans Louisiana.

Early Life and Education

Oliver Sartor serves as medical director of Tulane Cancer Center in New Orleans and holds the C. E. and Bernadine Laborde Professorship for cancer research, along with being part of Tulane University School of Medicine’s department of Medicine and Urology.

He serves on the Radiation Therapy Oncology Group’s Genitourinary Committee and as co-editor-in-chief for Clinical Genitourinary Cancer journal. Additionally, he has served on numerous other national and international advisory boards and committees.

At his death, Dr. Balfour Sartor is survived by his wife Gloria Sanderson Sartor; son Dr. Balfour Sartor; daughters Dr. Jennifer O’Driscoll, Rachel White and Amelie Walker-Yung as well as grandchildren Dr. Ella Grace Richardson, Madison Elizabeth Sanchez and Lane Gaaping Walker-Yung. Funeral services will be held September 21 at Noel United Methodist Church located on Herndon Ave in Alexandria.

Professional Career

Oliver Sartor has dedicated over three decades of his professional life to studying prostate cancer. As co-editor-in-chief of Clinical Genitourinary Cancer journal and assistant dean for Oncology at Tulane School of Medicine New Orleans. Additionally, he holds the C.E. and Bernadine Laborde Professorship in Cancer Research Medicine Urology Departments.

Volcanic eruptions in Iceland threatened to postpone delivery of radioligand therapy from Norway to Sartor’s lab at LSU Health Sciences Center in Shreveport on time, an experimental treatment which delivers radiation directly to cancer cells while protecting surrounding healthy tissue from damage.

Achievement and Honors

She kept a rock garden where she segregated “good snakes” from “bad snakes.” Additionally, she refused to kill one that damaged air conditioning insulation in her home.

Sartor has written numerous scholarly articles and serves as co-chair of the Radiation Therapy Oncology Group Genitourinary Committee since 2008. She also is one of the founding members of Shreveport Visual Arts Hall of Fame.

Oliver Sartor is an Oncology Professor at LSU Health Science Center in Shreveport, Louisiana. Specializing in prostate cancer care, he has led trials that led to FDA approvals for Samarium-153 EDTMP, Radium-223 and Cabazitaxel treatments as well as spearheaded several clinical research projects exploring new options for advanced prostate cancer patients.

Personal Life

Oliver Sartor is an internationally recognized expert on prostate cancer, having completed his fellowship at the National Cancer Institute in 1990. Since then he has published more than 300 peer-reviewed articles and led multiple national and international clinical trials, such as pivotal ones that led to FDA approval of Samarium-153 EDTMP, Radium-223 and Cabazitaxel; additionally he has lectured at events around 31 countries around the globe.

Sartor poses a challenging question to patients suffering from advanced prostate cancer: Would they like to experiment with an immunotherapy drug that has shown promise in other cancer types but has never been tried against prostate cancer? He serves as Assistant Dean for Oncology and C. E. and Bernadine Laborde Professor of Cancer Research in both Medicine and Urology departments at Tulane University School of Medicine in New Orleans.

Net Worth

Sartor, who specializes in medical oncology, has led multiple national and international clinical trials for prostate cancer. His research is focused on radioligand therapy – a form of cancer treatment which delivers radiation directly to tumor cells while sparing surrounding tissue – while in 2011 he founded the Blue Ribbon Soriee, an annual event to raise funds for his prostate cancer research, featuring silent and live auctions as well as consultant work for Advanced Accelerator Applications, Amgen, ArtBio, Astellas AstraZeneca Bayer Blue Earth Diagnostics Constellation Clovis Dendreon Endocyte Foundation Medicine Invitae Progenics Tenebio; with equity holdings held with both companies; holding equity interests within both RATIO and TELIX as well.

Leave a Reply

Your email address will not be published. Required fields are marked *